Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| J1I-MC-GZBX | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LY3437943 - Test | Experimental | A single dose of LY3437943 administered by subcutaneous (SC) injection via a test device (test formulation) |
|
| LY3437943 - Reference | Active Comparator | A single dose of LY3437943 administered by SC injection via a reference device (reference formulation) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY3437943 | Drug | Administered SC |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943 | PK: Cmax of LY3437943 | Predose up to 43 days postdose |
| PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943 | PK: AUC[0-tlast] of LY3437943 | Predose up to 43 days postdose |
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 | PK: AUC(0-∞) of LY3437943 | Predose up to 43 days postdose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qps-Mra, Llc | Miami | Florida | 33143-4875 | United States | ||
| ICON Early Phase Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000729679 | retatrutide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Test |
| Device |
Used to administer LY3437943 SC |
|
| Reference | Device | Used to administer LY3437943 SC |
|
| San Antonio |
| Texas |
| 78209 |
| United States |
| ICON | Salt Lake City | Utah | 84124 | United States |